telaprevir - 2/7

Entry	Author	Date	Location
Vertex Drug Gets Speedy FDA Review, BSX Buys Atritech, Ironwood Strikes Another Deal, & More Boston-Area Life Sciences News	Erin Kutz	01/21/11	Boston
Vertex Granted Speedy FDA Review	Luke Timmerman	01/20/11	Boston
Vertex Seeks FDA Green Light for Hepatitis C Drug; Chomps at the Bit For Fast Review	Luke Timmerman	11/23/10	Boston
Vertex Nails Third Big Trial With Hepatitis C Drug, In Toughest Patients to Treat	Luke Timmerman	09/07/10	Boston
Former Sirtris Execs Sell Resveratrol Via New Nonprofit, Dicerna Closes $25M Deal, ViThera Combats Gut Disease With Engineered Bacteria, & More Boston-Area Life Sciences News	Rebecca Zacks	08/13/10	Boston
Vertex’s Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C	Ryan McBride	08/10/10	Boston
How Lilly Let Telaprevir Go to Vertex, SV Focusing on Health IT With Latest Fund, Genzyme Isis Cholesterol Drug Shows Strong in Clinical Trial, & More Boston-Area Life Sciences News	Erin Kutz	08/06/10	Boston
Conatus Gets Idun, Trius Goes Public, BrainCells Gets Sabcomeline, & More San Diego-Area Life Sciences News	Bruce V. Bigelow	08/05/10	San Diego
Vertex Tops Merck	Ryan McBride	08/04/10	Boston
How Eli Lilly Let a Billion-Dollar Molecule Slip Away and Make a Fortune for Vertex	Ryan McBride	08/04/10	Boston
Concert Pharma Riding Potential $1B Glaxo Deal, Looks Ahead to Human Data on HIV Drug	Ryan McBride	07/14/10	Boston
FDA Approves Genzyme Pompe Drug, Vertex Hepatitis C Drug Trial Succeeds, Thermo Fisher Acquires Fermentas, & More Boston-Area Life Sciences News	Erin Kutz	05/28/10	Boston
Vertex Hepatitis C Drug Passes Pivotal Test, Cures Three Out of Every Four Patients	Luke Timmerman	05/25/10	Boston
Vertex Awaits Results of Hepatitis C Drug Trial, Helicos and Pfizer Cut Jobs, St. Jude Acquires LightLab, & More Boston-Area Life Sciences News	Erin Kutz	05/21/10	Boston
Vertex, Worth $7.5B, Eagerly Awaits Final Proof that Hepatitis C Drug Works	Luke Timmerman	05/17/10	Boston
Vertex Maps Out Combo Drug Game Plan for Treating Hepatitis C	Luke Timmerman	03/08/10	Boston
Avila Aims to Trump Vertex With Drug that Hits Hepatitis C Virus and Won’t Let Go	Luke Timmerman	02/26/10	Boston
Regulus, the MicroRNA Child of Isis and Alnylam, Strikes Potential $150M Deal with Glaxo	Luke Timmerman	02/25/10	San Diego
Vertex’s Matt Emmens on His Journey From Security Guard to CEO	Luke Timmerman	01/27/10	Boston
The Top Five Biotech Innovations of the 2000s	Clay Siegall	12/15/09	Seattle
Vertex Raises $443M in Yet Another Monster Stock Sale	Luke Timmerman	12/03/09	Boston
Vertex Hepatitis C Drug Wipes Out Virus For Toughest-to-Treat Patients	Luke Timmerman	10/28/09	Boston
Vertex Selling Telaprevir Payment Rights	Ryan McBride	07/10/09	Boston
Vertex Acquires Virochem for $375M to Make Cocktail Treatments For Hepatitis C	Luke Timmerman	03/03/09	Boston
Out With Hedge Funds, In With Blue Bloods: Vertex Transforms Investor Base Via Stock Sale	Luke Timmerman	02/20/09	Boston
Vertex Raises $320M in Secondary Stock Offering	Luke Timmerman	02/19/09	Boston
Vertex CEO Josh Boger Retiring In May; Matthew Emmens To Fill Role	Luke Timmerman	02/05/09	Boston
A Trio of Tysabri Stories, Genzyme’s Big Deal with Osiris, A Peek Inside a Winning Hedge Fund, & More Life Sciences News	Rebecca Zacks	11/05/08	Boston
Vertex Drug for Hepatitis C Shows Durable Virus-Killing Ability in Tough-to-Treat Patients	Luke Timmerman	11/01/08	Boston
Vertex Gears up for Big Liver Disease Conference	Luke Timmerman	10/29/08	Boston
Page 2 of 3	« previous page · next page »

Entry

Author

Date

Location

Vertex Drug Gets Speedy FDA Review, BSX Buys Atritech, Ironwood Strikes Another Deal, & More Boston-Area Life Sciences News

Erin Kutz

01/21/11

Boston

Vertex Granted Speedy FDA Review

Luke Timmerman

01/20/11

Boston